A Phase 4 interventional study of Oral iron supplementation and Intravenous iron supplementation in GastroIntestinal Bleeding and Anemia, sponsored by University of Pecs. Not yet recruiting at 1 site in Hungary. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by University of Pecs · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Anemia is a frequent complication of gastrointestinal bleeding, affecting 61% of the patients. Currently, anemia caused by gastrointestinal bleeding can be treated with iron supplementation. However, the dose and route of the administration are still a question. The FIERCE clinical trial aims to compare the effect of intravenous iron supplementation and oral iron replacement on mortality, unplanned emergency visits, and hospital readmissions in multimorbid patients with acute nonvariceal gastrointestinal bleeding.
In gastrointestinal bleeding (GIB) iron deficiency anemia (IDA) is a common complication, affecting more than 60% of the patients. There are two pillars of the treatment of acute GIB. First, the bleeding point needs identification and endoscopic treatment. Second, the resulting hypovolemia and anemia require fluid resuscitation, transfusion, and replacement of the lost iron. There are two simple ways to manage IDA after acute GIB. Patients either have intravenous (IV) iron infusions one to six times as part of their hospital treatment or receive three months of oral iron supplementation. There is a gap in current guidelines on which approach clinicians should choose.
Here the investigators plan a multicentric, two-arm, randomized controlled trial, to compare the efficacy of oral and intravenous iron supplementation in multimorbid patients with acute nonvariceal gastrointestinal bleeding. Patients will be randomly allocated in a 1:1 ratio to two groups. Group A will receive one dose of 1000 mg of IV ferric carboxymaltose on the day of randomization, while iron supplementation for group B will be performed with one ferrous sulfate tablet every day (ca. 200-300 mg) for three months. The primary outcome will be the composite outcome of all-cause mortality, unplanned emergency visit, and unplanned hospital readmission within six months after enrollment.
In the first phase, the investigators plan to recruit 15 patients on each arm to assess the proportion of the primary outcome in the two groups. In the second phase, a sample size calculation for the primary outcome will be performed based on the results of the first phase.
338 studies on the registry are indexed under Gastrointestinal Hemorrhage; 77 are open to participants now.
This study's planned enrollment of 570 is above the median of 98 across 210 interventional studies indexed under Gastrointestinal Hemorrhage.
Browse Gastrointestinal Hemorrhage studies →University of Pecs is the lead sponsor of 107 studies on the registry; 25 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to receive oral ferrous sulfate, ca. 200-300 mg every day for 3 months.
Drug: Oral iron supplementation
Patients randomized to receive one dose of 1000 mg intravenous ferric carboxymaltose.
Drug: Intravenous iron supplementation
Ca. 200-300 mg of ferrous sulfate will be administered orally every day for 3 months.
One dose of intravenous 1000 mg ferric carboxymaltose will be administered on the day of randomization.
Composite outcome
The composite endpoint includes all-cause mortality, unplanned emergency visit (general practitioner or emergency outpatient clinic), and unplanned hospital admission for any reason. The investigators will calculate the proportion of the outcome in each arm.
Time frame: 3 months
All-cause mortality
Death from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of mortality.
Time frame: 1, and 3 months
Unplanned emergency visits
Emergency visit from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of unplanned emergency visits.
Time frame: 1, and 3 months
Unplanned hospital admission
Hospital admission from any cause. The proportion of the outcome will be calculated in each arm and compared between the arms. The investigators will compare subgroups of patients based on the cause of unplanned admission.
Time frame: 1, and 3 months
Quality of life using the 36-Item Short-Form Health Survey
Changes in quality of life measured with the 36-Item Short-Form Health Survey (SF-36) questionnaire compared to baseline.
Time frame: 1, and 3 months +/- 7 days
Quality of life using the EuroQol five-dimensions - 5 levels questionnare
Changes in quality of life measured with the EuroQol five-dimensions - 5 levels (EQ-5D-5L) questionnaire compared to baseline.
Time frame: 1, and 3 months +/- 7 days
Gait speed
Changes in gait speed compared to baseline. Gait speed will be evaluated on a 4-meter flat walking path.
Time frame: 1, and 3 months +/- 7 days
Six-Minute Walk Test (6MWT)
Changes in Six-Minute Walk Test (6MWT) compared to baseline.
Time frame: 1, and 3 months +/- 7 days
Handgrip strength
Changes in handgrip strength compared to baseline.
Time frame: 1, and 3 months +/- 7 days
Normalization of the haemoglobin level
The percentage of participants with Hb levels of ≥12 g/dL in women and ≥13 g/d, compared to baseline.
Time frame: 1, and 3 months +/- 7 days
Change in Hb level
Absolute change from baseline to follow-up in Hb level.
Time frame: 1, and 3 months +/- 7 days
Change in haematocrit
Absolute change from baseline to follow-up in haematocrit.
Time frame: 1, and 3 months +/- 7 days
Change in serum iron level
Absolute change from baseline to follow-up in serum iron level.
Time frame: 1, and 3 months +/- 7 days
Change in serum transferrin level
Absolute change from baseline to follow-up in serum transferrin level.
Time frame: 1, and 3 months +/- 7 days
Change in transferrin saturation
Absolute change from baseline to follow-up in transferrin saturation.
Time frame: 1, and 3 months +/- 7 days
Change in soluble transferrin receptor concentration
Absolute change from baseline to follow-up in soluble transferrin receptor (sTfR) concentration.
Time frame: 1, and 3 months +/- 7 days
Change in ferritin level
Absolute change from baseline to follow-up in ferritin level.
Time frame: 1, and 3 months +/- 7 days
Change in the number of reticulocytes
Absolute change from baseline to follow-up in the number of reticulocytes.
Time frame: 1, and 3 months +/- 7 days
Change in the number of erythrocytes
Absolute change from baseline to follow-up in the number of erythrocytes.
Time frame: 1, and 3 months +/- 7 days
Change in the total iron-binding capacity
Absolute change from baseline to follow-up in the total iron-binding capacity (TIBC).
Time frame: 1, and 3 months +/- 7 days
Change in erythropoietin level
Absolute change from baseline to follow-up in erythropoietin level.
Time frame: 1, and 3 months +/- 7 days
Change in C-reactive protein level
Absolute change from baseline to follow-up in the C-reactive protein level.
Time frame: 1, and 3 months +/- 7 days
Change in hepcidin level
Absolute change from baseline to follow-up in hepcidin level.
Time frame: 1, and 3 months +/- 7 days
Change in phosphate level
Absolute change from baseline to follow-up in phosphate level.
Time frame: 1, and 3 months +/- 7 days
Discontinuation of the treatment due to adverse events
The percentage of discontinuation in the two arms.
Time frame: 1, and 3 months +/- 7 days
Cost-effectiveness
The incremental cost-effectiveness ratio (ICER): incremental costs divided by incremental effectiveness .
Time frame: 1, and 3 months +/- 7 days
Plan to share: No
Start is estimated for Sep 2025; primary completion for Dec 2027, 27 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.